Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1

eLife

Volumn 2013, Issue 2, 2013, Pages

  Luo, Ling ^a,b   Uehara, Hironori ^a   Zhang, Xiaohui ^a   Das, Subrata K ^a   Olsen, Thomas ^a   Holt, Derick ^a   Simonis, Jacquelyn M ^a   Jackman, Kyle ^a   Singh, Nirbhai ^a   Miya, Tadashi R ^a   Huang, Wei ^a   Ahmed, Faisal ^a   Bastos Carvalho, Ana ^c   Le, Yun Zheng ^d   Mamalis, Christina ^a   Chiodo, Vince A ^e   Hauswirth, William W ^e   Baffi, Judit ^c   Lacal, Pedro M ^f   Orecchia, Angela ^f   Ferrara, Napoleone ^g,l   Gao, Guangping ^a,h   Young hee, Kim ^c   Fu, Yingbin ^a   Owen, Leah ^a   Albuquerque, Romulo ^c   Baehr, Wolfgang ^a   Thomas, Kirk ^a   Li, Dean Y ^a   Chalam, Kakarla V ^e   Shibuya, Masabumi ⁱ   Grisanti, Salvatore ^j   Wilson, David J ^k   Ambati, Jayakrishna ^c   Ambati, Balamurali K ^a   more..

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b 306 HOSPITAL OF PLA   (China)

^c UNIVERSITY OF KENTUCKY   (United States)

^d UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

^f LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^g GENENTECH INC   (United States)

^h UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

ⁱ JOBU UNIVERSITY   (Japan)

^j UNIVERSITY OF LÜBECK   (Germany)

^k OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 1; ANTIBODY; FLT1 PROTEIN, HUMAN; FLT1 PROTEIN, MOUSE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MOUSE; NONHUMAN; OPHTHALMOSCOPY; PHOTORECEPTOR; PHOTOTRANSDUCTION; PIGMENT EPITHELIUM; RETINA MACULA AGE RELATED DEGENERATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SUBRETINAL NEOVASCULARIZATION; TRANSMISSION ELECTRON MICROSCOPY; VASCULARIZATION; WESTERN BLOTTING; ADULT; AGED; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; C57BL MOUSE; CASE CONTROL STUDY; DEFICIENCY; DISEASE MODEL; DOWN REGULATION; GENETICS; KNOCKOUT MOUSE; MACULAR DEGENERATION; METABOLISM; PATHOLOGY; PHOTORECEPTOR CELL; RETINA NEOVASCULARIZATION; VERY ELDERLY; VISION;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES; CASE-CONTROL STUDIES; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FEMALE; HUMANS; MACULAR DEGENERATION; MALE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; PHOTORECEPTOR CELLS, VERTEBRATE; RETINAL NEOVASCULARIZATION; RETINAL PIGMENT EPITHELIUM; RNA INTERFERENCE; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VISION, OCULAR;

EID: 84879298265     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.00324     Document Type: Article

References (59)

1. Ahlers C, Golbaz I, Stock G, Fous A, Kolar S, Pruente C, et al. 2008. Time course of morphologic effects on different retinal compartments after ranibizumab therapy in age-related macular degeneration. Ophthalmology 115:e39-46. doi: 10.1016/j.ophtha.2008.05.017.
2. Ahmad S, Hewett PW, Al-Ani B, Sissaoui S, Fujisawa T, Cudmore MJ, et al. 2011. Autocrine activity of soluble Flt-1 controls endothelial cell function and angiogenesis. Vasc Cell 3:15. doi: 10.1186/2045-824X-3-15.
3. Ambati J, Anand A, Fernandez S, Sakurai E, Lynn BC, Kuziel WA, et al. 2003a. An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice. Nat Med 9:1390-7. doi: 10.1038/nm950.
4. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. 2003b. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 48:257-93. doi: 10.1016/S0039-6257(03)00030-4.
5. Ambati BK, Nozaki M, Singh N, Takeda A, Jani PD, Suthar T, et al. 2006. Corneal avascularity is due to soluble VEGF receptor-1. Nature 443:993-7. doi: 10.1038/nature05249.
6. Ambati BK, Patterson E, Jani P, Jenkins C, Higgins E, Singh N, et al. 2007. Soluble vascular endothelial growth factor receptor-1 contributes to the corneal antiangiogenic barrier. Br J Ophthalmol 91:505-8. doi: 10.1136/bjo.2006.107417.
7. Amin R, Puklin JE, Frank RN. 1994. Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. Invest Ophthalmol Vis Sci 35:3178-88.
8. Baldwin ME, Liang XH, Ruchatz A, Busch J, Zhenyu G, Roose-Girma M, Olsson C, Erickson S, Ferrara N, Gerber H-P. 2004. Generation of mice carrying floxed VEGFR-1 and VEGFR-2 alleles to study the effects of postnatal gene ablation on angiogenesis and hematopoiesis. Proc Amer Assoc Cancer Res 45. http://www.aacrmeetingabstracts.org/cgi/content/abstract/2004/1/596-c.
9. Bhutto IA, Uno K, Merges C, Zhang L, McLeod DS, Lutty GA. 2008. Reduction of endogenous angiogenesis inhibitors in Bruch's membrane of the submacular region in eyes with age-related macular degeneration. Arch Ophthalmol 126:670-8. doi: 10.1001/archopht.126.5.670.
10. Bill A, Sperber G, Ujiie K. 1983. Physiology of the choroidal vascular bed. Int Ophthalmol 6:101-7. doi: 10.1007/BF00127638.
11. Blaauwgeers HG, Holtkamp GM, Rutten H, Witmer AN, Koolwijk P, Partanen TA, et al. 1999. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol 155:421-8. doi: 10.1016/S0002-9440(10)65138-3.
12. Carmeliet P, Jain RK. 2011. Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298-307. doi: 10.1038/nature10144.
13. Donati MC, Carifi G, Virgili G, Menchini U. 2006. Retinal angiomatous proliferation: association with clinical and angiographic features. Ophthalmologica 220:31-6. doi: 10.1159/000089272.
14. Editorial. 2007. Toxic alert. Nature 449:378. doi: 10.1038/449378a.
15. Fischer C, Mazzone M, Jonckx B, Carmeliet P. 2008. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer 8:942-56 doi: 10.1038/nrc2524.
16. Fong GH, Rossant J, Gertsenstein M, Breitman ML. 1995. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376:66-70. doi: 10.1038/376066a0.
17. Furino C, Ferrara A, Cardascia N, Besozzi G, Alessio G, Sborgia L, et al. 2009. Combined cataract extraction and intravitreal bevacizumab in eyes with choroidal neovascularization resulting from age-related macular degeneration. J Cataract Refract Surg 35:1518-22. doi: 10.1016/j.jcrs.2009.04.032.
18. Gerber HP, Hillan KJ, Ryan AM, Kowalski J, Keller GA, Rangell L, et al. 1999. VEGF is required for growth and survival in neonatal mice. Development 126:1149-59.
19. Giani A, Thanos A, Roh MI, Connolly E, Trichonas G, Kim I, et al. 2011. In vivo evaluation of laser-induced choroidal neovascularization using spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci 52:3880-87. doi: 10.1167/iovs.10-6266.
20. Heckenlively JR, Hawes NL, Friedlander M, Nusinowitz S, Hurd R, Davisson M, et al. 2003. Mouse model of subretinal neovascularization with choroidal anastomosis. Retina 23:518-22 doi: 10.1097/00006982-200308000-00012.
21. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M. 1998. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 95:9349-54.
22. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. 2004. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 56:549-80. doi: 10.1124/pr.56.4.3.
23. Imamura Y, Noda S, Hashizume K, Shinoda K, Yamaguchi M, Uchiyama S, et al. 2006. Drusen, choroidal neovascularization, and retinal pigment epithelium dysfunction in SOD1-deficient mice: a model of age-related macular degeneration. Proc Natl Acad Sci USA 103:11282-7. doi: 10.1073/pnas.0602131103.
24. Jin J, Sison K, Li C, Tian R, Wnuk M, Sung HK, et al. 2012. Soluble FLT1 binds lipid microdomains in podocytes to control cell morphology and glomerular barrier function. Cell 151:384-99. doi: 10.1016/j.cell.2012.08.037.
25. Joeres S, Tsong JW, Updike PG, Collins AT, Dustin L, Walsh AC, et al. 2007. Reproducibility of quantitative optical coherence tomography subanalysis in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 48:4300-7. doi: 10.1167/iovs.07-0179.
26. Kachi S, Oshima Y, Esumi N, Kachi M, Rogers B, Zack DJ, et al. 2005. Nonviral ocular gene transfer. Gene Ther 12:843-51. doi: 10.1038/sj.gt.3302475.
27. Kaneko H, Dridi S, Tarallo V, Gelfand BD, Fowler BJ, Cho WG, et al. 2011. DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature 471:325-30. doi: 10.1038/nature09830.
28. Kappas NC, Zeng G, Chappell JC, Kearney JB, Hazarika S, Kallianos KG, et al. 2008. The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood vessel branching. J Cell Biol 181:847-58. doi: 10.1083/jcb.200709114.
29. Kendall RL, Thomas KA. 1993. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 90:10705-9.
30. Kendall RL, Wang G, Thomas KA. 1996. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 226:324-8. doi: 10.1006/bbrc.1996.1355.
31. Kjellstrom S, Bush RA, Zeng Y, Takada Y, Sieving PA. 2007. Retinoschisin gene therapy and natural history in the Rs1h-KO mouse: long-term rescue from retinal degeneration. Invest Ophthalmol Vis Sci 48:3837-45. doi: 10.1167/iovs.07-0203.
32. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, et al. 2005. Complement factor H polymorphism in age-related macular degeneration. Science 308:385-9. doi: 10.1126/science.1109557.
33. Kleinman ME, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, Baffi JZ, et al. 2008. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452:591-7. doi: 10.1038/nature06765.
34. Lai CM, Shen WY, Brankov M, Lai YK, Barnett NL, Lee SY, et al. 2005. Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys. Mol Ther 12:659-68. doi: 10.1016/j. ymthe.2005.04.022.
35. Le YZ, Zheng W, Rao PC, Zheng L, Anderson RE, Esumi N, et al. 2008. Inducible expression of cre recombinase in the retinal pigmented epithelium. Invest Ophthalmol Vis Sci 49:1248-53. doi: 10.1167/iovs.07-1105.
36. Li S, Chen D, Sauve Y, McCandless J, Chen YJ, Chen CK. 2005. Rhodopsin-iCre transgenic mouse line for Cre-mediated rod-specific gene targeting. Genesis 41:73-80. doi: 10.1002/gene.20097.
37. Line BR, Mitra A, Nan A, Ghandehari H. 2005. Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates. J Nucl Med 46:1552-60.
38. Lukason M, DuFresne E, Rubin H, Pechan P, Li Q, Kim I, et al. 2011. Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule. Mol Ther 19:260-5. doi: 10.1038/mt.2010.230.
39. Luo L, Zhang X, Hirano Y, Tyagi P, Barabas P, Uehara H, et al. 2013. Targeted intraceptor nanoparticle therapy reduces angiogenesis and fibrosis in primate and murine macular degeneration. ACS Nano 7:3264-75. doi: 10.1021/nn305958y.
40. Malik AK, Baldwin ME, Peale F, Fuh G, Liang WC, Lowman H, et al. 2006. Redundant roles of VEGF-B and PlGF during selective VEGF-A blockade in mice. Blood 107:550-7. doi: 10.1182/blood-2005-05-2047.
41. Meier ID, Bernreuther C, Tilling T, Neidhardt J, Wong YW, Schulze C, et al. 2010. Short DNA sequences inserted for gene targeting can accidentally interfere with off-target gene expression. FASEB J 24:1714-24. doi: 10.1096/fj.09-140749.
42. Okamoto N, Tobe T, Hackett SF, Ozaki H, Vinores MA, LaRochelle W, et al. 1997. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol 151:281-91.
43. Orecchia A, Lacal PM, Schietroma C, Morea V, Zambruno G, Failla CM. 2003. Vascular endothelial growth factor receptor-1 is deposited in the extracellular matrix by endothelial cells and is a ligand for the alpha 5 beta 1 integrin. J Cell Sci 116:3479-89. doi: 10.1242/jcs.00673.
44. Potente M, Gerhardt H, Carmeliet P. 2011. Basic and therapeutic aspects of angiogenesis. Cell 146:873-87. doi: 10.1016/j.cell.2011.08.039.
45. Rajappa M, Saxena P, Kaur J. 2010. Ocular angiogenesis: mechanisms and recent advances in therapy. Adv Clin Chem 50:103-21.
46. Ruggeri M, Tsechpenakis G, Jiao S, Jockovich ME, Cebulla C, Hernandez E, et al. 2009. Retinal tumor imaging and volume quantification in mouse model using spectral-domain optical coherence tomography. Opt Express 17:4074-83.
47. Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiyama E, Kurihara T, et al. 2008. Endogenous VEGF is required for visual function: evidence for a survival role on Muller cells and photoreceptors. PLOS ONE 3:e3554. doi: 10.1371/journal.pone.0003554.
48. Saint-Geniez M, Kurihara T, Sekiyama E, Maldonado AE, D'Amore PA. 2009. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci USA 106:18751-6. doi: 10.1073/ pnas.0905010106.
49. Schlichtenbrede FC, da Cruz L, Stephens C, Smith AJ, Georgiadis A, Thrasher AJ, et al. 2003. Long-term evaluation of retinal function in Prph2Rd2/Rd2 mice following AAV-mediated gene replacement therapy. J Gene Med 5:757-64. doi: 10.1002/jgm.401.
50. Schmidt-Supprian M, Rajewsky K. 2007. Vagaries of conditional gene targeting. Nat Immunol 8:665-8. doi: 10.1038/ni0707-665.
51. Schmucker C, Schaeffel F. 2004. A paraxial schematic eye model for the growing C57BL/6 mouse. Vision Res 44:1857-67. doi: 10.1016/j.visres.2004.03.011.
52. Schwesinger C, Yee C, Rohan RM, Joussen AM, Fernandez A, Meyer TN, et al. 2001. Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. Am J Pathol 158:1161-72. doi: 10.1016/S0002-9440(10)64063-1.
53. Shao J, Tian L, Lei B, Wei L, Yang Y, Kijlstra A, et al. 2012. AAV2-mediated subretinal gene transfer of mIL-27p28 attenuates experimental autoimmune uveoretinitis in mice. PLOS ONE 7:e37773. doi: 10.1371/journal.pone.0037773.
54. Sun T, Storb U. 2001. Insertion of phosphoglycerine kinase (PGK)-neo 5' of Jlambda1 dramatically enhances VJlambda1 rearrangement. J Exp Med 6:699-712. doi: 10.1084/jem.193.6.699.
55. Tatar O, Shinoda K, Kaiserling E, Claes C, Eckardt C, Eckert T, et al. 2009. Implications of bevacizumab on vascular endothelial growth factor and endostatin in human choroidal neovascularisation. Br J Ophthalmol 93:159-65. doi: 10.1136/bjo.2008.138594.
56. Yang L, Luo L, Ji W, Gong C, Wu D, Huang H, et al. 2013. Effect of low dose bisphenol A on the early differentiation of human embryonic stem cells into mammary epithelial cells. Toxicol Lett 218:187-93. doi: 10.1016/j. toxlet.2013.01.026.
57. Zhang F, Tang Z, Hou X, Lennartsson J, Li Y, Koch AW, et al. 2009. VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci USA 106:6152-7. doi: 10.1073/pnas.0813061106.
58. Zhao S, Gu Y, Fan R, Groome LJ, Cooper D, Wang Y. 2010. Proteases and sFlt-1 release in the human placenta. Placenta 31:512-8. doi: 10.1016/j.placenta.2010.03.014.
59. Zhao Z, Chen Y, Wang J, Sternberg P, Freeman ML, Grossniklaus HE, et al. 2011. Age-related retinopathy in NRF2-deficient mice. PLOS ONE 6:e19456. doi: 10.1371/journal.pone.0019456.